Evidence map›Paper›PMID 42082719›Full record

ArticleNature genetics2026

Transposable elements shape stemness in normal and leukemic hematopoiesis.

Giacomo Grillo, Bettina Nadorp, Aditi Qamra, Bryce Drylie, Amanda Mitchell, Christopher Arlidge, Ankita Nand, Naoya Takayama, Alex Murison, Seyed Ali Madani Tonekaboni and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Giacomo Grillo *Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Bettina Nadorp *Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-1974-8425
Aditi QamraPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Bryce DrylieCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK.ORCID http://orcid.org/0000-0002-5978-962X
Amanda MitchellPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Christopher ArlidgePrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Ankita NandPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-7071-5114
Naoya TakayamaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-6867-1677
Alex MurisonPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Seyed Ali Madani TonekaboniPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Komaldeep Kaur KangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Andrea ArrudaDivision of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
Jean C Y WangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Özgen DenizCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK.ORCID http://orcid.org/0000-0001-7268-1923
Héléna BoutzenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
John E DickPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. john.dick@uhn.ca.ORCID http://orcid.org/0000-0002-9527-8317
Mathieu LupienPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. mathieu.lupien@uhn.ca.ORCID http://orcid.org/0000-0003-0929-9478

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) JP17K09899
6 · The paper itself

Abstract

Despite most acute myeloid leukemia (AML) patients achieving complete remission after induction chemotherapy, two-thirds relapse within 5 years. AML follows a cellular hierarchy sustained by leukemia stem cells (LSCs), which drive tumor progression and relapse. Little is known about the genetic determinants driving LSCs stemness properties. By identifying chromatin variants from accessibility measurements across LSCs, hematopoietic stem cells and downstream progeny, we identified transposable elements (TEs) as genetic determinants of primitive versus mature populations. Accessibility at 121 TE subfamilies distinguished LSCs from mature leukemic cells and stratified AML patients by stemness and survival. Functional assays revealed that these TE subfamilies serve as docking sites for genome topology regulators or lineage-specific transcription factors, including LYL1 in LSCs. Chromatin editing established the necessity of accessibility at LTR12C elements to maintain LSC stemness. Thus, TEs regulate primitive versus mature cell states, with distinct subfamilies underlying stemness in normal versus leukemic stem cells.

Indexed as

DNA Transposable ElementsHematopoiesisLeukemia, Myeloid, AcuteNeoplastic Stem CellsAnimalsChromatinHematopoietic Stem CellsHumansChromatinDNA Transposable Elements

Identifiers

PMID42082719
PMCPMC13175892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.